The quickest route to profitability is Covid. With profits, all trials for all indications can be funded. In the short run, efficacy in Covid will create the economic capability for CYDY to reach its potential. Without it, you're back to 75 cents a share and scrounging for investors to survive.

The short-term picture enables the long-term. I believe in the long-term capability of the drug. The fastest way for CYDY to make it happen is to get it approved for Covid. Truthfully, at this point nothing else matters because with enough funds, you can catch up very quickly. Without the funding, CYDY is a beggar and we're looking at years of scrounging to get anything done. That's the reality.